Gilead Stock Forecast: Can Pricing Pressure and Competition Stop Gilead’s 5-year Bull Run?
Reuben Bor is a Financial Analyst Intern at I Know First.
- Gilead Sciences has returned over 330% to shareholders in the past 5 years
- Merck has released a rival Hepatitis C drug that is substantially cheaper than Gilead’s Harvoni
- Massachusetts’s Attorney General has threatened the company with legal action concerning the company’s pricing policies
- Gilead Stock 2016 Outlook